Market News & Trends
LifeArc & Milner Therapeutics Institute Announce Partnership in Artificial Intelligence & Machine Learning
LifeArc and the Milner Therapeutics Institute at the University of Cambridge, recently announced a new partnership to identify and validate new drug targets in immuno-oncology…
Hovione Strengthens Inhalation Services Portfolio
Hovione recently announced that a new MG2 Tekna Precision Capsule filling unit is now online in its Portugal facilities. This investment reinforces Hovione’s Services portfolio…
Cynata Announces Encouraging Results; DSMB Recommendation Next Stage
Australian stem cell and regenerative medicine company, Cynata Therapeutics, recently announced that the independent Data Safety Monitoring Board (DSMB) has recommended that Cynata’s clinical trial…
Avacta & Oncosec to Collaborate on Innovative Gene Delivery
Avacta & Oncosec to Collaborate on Innovative Gene Delivery Avacta Group plc and OncoSec Medical Incorporated recently announced they have entered into a research collaboration…
RedHill Biopharma Announces Final Results from Phase II Study
RedHill Biopharma Ltd. recently announced top-line final results from the Phase II clinical study with BEKINDA 12 mg (RHB-102) for the treatment of diarrhea-predominant irritable…
Biolog Announces Mitochondrial Assay Breakthrough
Biolog, Inc. recently announced the launch of a new product line that enables a comprehensive scan of mitochondrial function. Better technology for measuring mitochondrial function…
PPD & Quotient Sciences Form Innovative Partnership to Accelerate Pediatric Drug Development
Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), and Quotient Sciences (Quotient), a drug development services organization, recently announced a new…
Marina Biotech Announces Drug Development & Licensing Agreement With Autotelic Bio
Marina Biotech, Inc. recently announced it has entered into a binding agreement with Autotelic Bio Inc., to enter into a license of Marina’s IT-103 clinical…
Avacta Group Announces Positive Outcome of Proof-of-Concept Study
Avacta Group plc recently announced its initial study with Glythera Limited, the developer of next-generation antibody drug conjugates, has concluded successfully. Following this study, the…
OWKIN Closes $11-Million Financing for AI in Drug Development
OWKIN, a predictive analytics company that utilizes transfer learning to accelerate drug discovery and development, recently announced an $11-million Series A funding round, led by…
Colorcon Transforms the Sugar Coating Process With a New Opadry System
Colorcon Inc. recently announces an exciting process development for sugar coated pharmaceutical tablets with the launch of Opadry® SGR, Rapid Sugar Film Coating System. This…
Sanofi to Acquire Bioverativ for $11.6 Billion
Sanofi and Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders, have entered into a definitive agreement under which…
Next Breath Announces Injectable Extractable & Leachable Services
Next Breath, a division of AptarGroup, is pleased to announce the extension of their cGMP analytical services to include development services for injectable delivery systems,…
CTI BioPharma to Receive $10-Million Milestone
CTI BioPharma recently announced that it expects to receive a $10-million milestone payment in February 2018 from Teva Pharmaceutical Industries related to the achievement of…
Pandion Therapeutics Announces $58-Million Financing to Advance Tissue-Specific Immune Modulator Drugs
Pandion Therapeutics, Inc. recently announced the completion of a $58-million Series A financing. This funding will be used to advance its initial drug programs for…
Syndax Announces Clinical Collaboration With Genentech
Syndax Pharmaceuticals Inc. recently announced a new clinical collaboration with Genentech, a member of the Roche Group. As part of the collaboration, the two companies…
ARCA Biopharma Announces Completion of GENETIC-AF Phase 2B Clinical Trial
ARCA Biopharma, Inc. recently announced the completion of patient follow-up for GENETIC-AF, a Phase 2B, double-blind, superiority clinical trial evaluating Gencaro (bucindolol hydrochloride) as a…
Teneobio Announces Strategic Alliance With TESARO
Teneobio, Inc., a next-generation multi-specific antibody therapeutics company, recently announced the initiation of a research collaboration and licensing agreement with TESARO, Inc., an oncology-focused biopharmaceutical…
ProQR & Galapagos Announce Research Collaboration
ProQR Therapeutics N.V. recently announced it has entered into a research collaboration agreement with Galapagos N.V. Under the agreement, the two companies will work together…
CymaBay Therapeutics Receives $5-Million Milestone Payment
CymaBay Therapeutics, Inc. recently announced it has received a $5-million milestone payment from Kowa Pharmaceuticals America for the initiation of a study evaluating the pharmacokinetics…
